Cognos Therapeutics to go public via a SPA merger with Nocturne Acquisition in a $120m deal.

Cognos Therapeutics, a developer of diagnostic devices, agreed to go public via a SPA merger with Nocturne Acquisition in a $120m deal. "With over 15 years of research and development, Cognos has laid out a roadmap to deliver a novel targeted solution in the important field of brain cancer. Cognos' SINNAIS has the potential to become the world's first implantable device for local and metronomic delivery of therapeutics for treatment of neurological diseases. SINNAIS will enable unprecedented, targeted delivery of chemotherapeutics for persistent glioma and other solid tumors. It will provide physicians with an effective alternative method to monitor and treat tumor-based brain cancer and other neurological diseases," Henry Monzon, Nocturne Chairman and CEO.